A phase 2, randomized, double‐blind, placebo‐controlled study of GS‐9450 in subjects with nonalcoholic steatohepatitis
Vlad Ratziu, Muhammad Y. Sheikh, Arun J. Sanyal, Joseph K. Lim, Hari Conjeevaram, Naga Chalasani, Manal Abdelmalek, Anezi Bakken, Christophe Renou, Melissa Palmer, Robert A. Levine, B. Raj Bhandari, Melanie Cornpropst, Wei Liang, Benjamin King, Elsa Mondou, Franck S. Rousseau, John McHutchison, Mario Chojkier – 17 October 2011 – In nonalcoholic steatohepatitis (NASH), the extent of hepatocyte apoptosis correlates with disease severity. Reducing hepatocyte apoptosis with the selective caspase inhibitor GS‐9450 has a potential for altering the course of the liver disease.